The main clinical trial evidence to support the use of setmelanotide for the treatment of obesity and hyperphagia caused by POMC or LEPR deficiency was provided by two multicentre phase III trials conducted in North America and Europe.78 The POMC trial (ClinicalTrials.gov identifier: NCT02896192) and the LEPR trial (ClinicalTrials.gov identifier: NCT03287960) included participants aged ≥6 years with obesity caused by POMC and LEPR deficiency, respectively. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.